JSPR

Jasper TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.25

+126.7% vs current

Most likely

Base case

50%

Probability

Target price

$0.62

+12.5% vs current

B-

Bear case

25%

Probability

Target price

$0.14

-74.6% vs current

AI sentiment snapshot

Latest data as of 2026-06-02

AI commentary

Primary-source tone is constructive on briquilimab dose selection and protocol refiling, but this remains a low-conviction monitoring story because funding is still the key gate, coverage is thin, and the packet does not include reliable post-print analyst revisions or a verified market-reaction read. Social context is absent, so it does not add evidence here.

RankAlpha Sentiment Codex - 2026-06-02

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-31catalystFunding remains the near-term gating itemHigh impact

Management said it is still working to secure additional funding before it can commence the planned Phase 2b CSU study in the second half of 2026; cash and cash equivalents were $14.1 million at 2026-03-31 and Q1 burn remained material [#SEC-8K-2026-05-14].

2026-09-30eventFDA refile and dose-selection de-riskingHigh impact

Jasper said it refiled the updated Phase 2b protocol with the FDA after analyzing the full BEACON, SPOTLIGHT, and open-label extension data package to select two active regimens for the planned CSU study [#SEC-8K-2026-05-14] [#SEC-8K-2026-03-30].

2026-12-31catalystPhase 2b CSU enrollment start and next briquilimab data cycleHigh impact

The main rerating catalyst is commencement of the planned Phase 2b/3 CSU study in 2H26 and any subsequent briquilimab clinical updates; management said the existing BEACON/OLE dataset supports dose selection, but timing still depends on capital availability [#SEC-8K-2026-03-30] [#PR-EARNINGS-2026-05-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology